Could a common diabetes drug help heal the gut in short bowel syndrome?

NCT ID NCT07297238

Completed Disease control Sponsor: Jinling Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 15, 2026 · Updated 3 times

Summary

This study tests whether semaglutide, a drug used for diabetes, can improve intestinal barrier function in adults with short bowel syndrome who need intravenous nutrition. Twenty participants will receive either semaglutide or a placebo for 28 days. Researchers will measure blood markers of gut health and nutrient absorption.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide (a GLP-1 receptor agonist)
What this could lead to: If it works, this could point toward a new way to help people with short bowel syndrome absorb nutrients better and rely less on intravenous feeding.
What could go wrong: This is a very small, early-stage trial with only 20 people over 28 days. The results may not apply to everyone, and the treatment might not improve gut function as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTESTINAL FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic intestinal failure Intestinal Failure short bowel syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTESTINAL FAILURE SHORT BOWEL SYNDROME (SBS)

Contacts and locations

Show contact details

Locations

Jinling Hospital

Nanjing, China, 210002, China
Jinling Hospital

Nanning, China, 210002, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.